Neurofibromatosis (NF) and Schwannomatosis can involve skin changes, hearing loss, vision issues, and nerve tumors, but may go unrecognized for years. Neuro-oncologists Katie Metrock, M.D., and Rebecca Brown, M.D., discuss how these two distinct genetic conditions are classified, how they typically present, and how newly approved MEK inhibitors are shaping treatment.